Artal Group’s Agios Pharmaceuticals AGIO Stock Holding History

Artal Group’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100,000	Closed	-$4.99M	–	103
2019 Q2	$4.99M	Sell	100,000 -100,000	-50%	-$5.34M	0.2%	79
2019 Q1	$13.5M	Hold	200,000	–	–	0.55%	42
2018 Q4	$9.22M	Buy	+200,000	New	+$12.3M	0.34%	49
2018 Q3	–	Sell	-50,000	Closed	-$4.21M	–	106
2018 Q2	$4.21M	Hold	50,000	–	–	0.09%	72
2018 Q1	$4.09M	Sell	50,000 -50,000	-50%	-$3.86M	0.05%	79
2017 Q4	$5.72M	Buy	+100,000	New	+$6.29M	0.09%	66
2017 Q3	–	Sell	-100,000	Closed	-$5.14M	–	113
2017 Q2	$5.14M	Hold	100,000	–	–	0.09%	61
2017 Q1	$5.84M	Sell	100,000 -500,000	-83%	-$24M	0.13%	57
2016 Q4	$25M	Buy	600,000 +100,000	+20%	+$5.25M	0.56%	20
2016 Q3	$26.4M	Buy	+500,000	New	+$21.8M	0.52%	21
2016 Q2	–	Sell	-200,000	Closed	-$8.12M	–	71
2016 Q1	$8.12M	Buy	200,000 +100,000	+100%	+$4.28M	0.16%	38
2015 Q4	$6.49M	Buy	+100,000	New	+$6.56M	0.12%	58

Other funds holding AGIO

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group's AGIO Position: Q3 2020 in Review

Artal Group sold out of Agios Pharmaceuticals (AGIO) in Q3 2020, closing a stake of 376,000 shares — an estimated $20.1M sold.

Artal Group first reported a position in AGIO in Q3 2013 and held it in 28 quarters. The position peaked at $43.8M in Q1 2017. 214 funds tracked by Wall St. Rank hold AGIO as of Q3 2020.

Artal Group reported no remaining Agios Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Artal Group sold 376,000 Agios Pharmaceuticals shares in Q3 2020, an estimated $20.1M.
Artal Group first reported a position in Agios Pharmaceuticals in Q3 2013 and held it in 28 quarters.
Artal Group's Agios Pharmaceuticals position peaked at $43.8M in Q1 2017.
214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2020.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.